PROMEDIGEN
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PROMEDIGEN - overview
Established
2019
Location
Daejeon, -, South Korea
Primary Industry
Biotechnology
About
Based in South Korea, PROMEDIGEN is a biotechnology firm that develops advanced treatments for cancer and neurodegenerative disorders utilizing proprietary protein engineering technologies. Founded in 2019 in Daejeon, South Korea, PROMEDIGEN is focused on biotechnology solutions for serious medical conditions. In June 2020, the company secured KRW 2 billion in funding from Company K Partners, marking its initial venture funding round. The founder's background, including any previous ventures, is not disclosed.
PROMEDIGEN specializes in creating innovative treatments targeting cancer and neurodegenerative disorders through its proprietary technology for post-translational modifications (PTMs) in proteins. This technology allows for the production of uniquely modified proteins associated with cancer-specific targets, addressing challenges such as drug resistance. The company serves healthcare providers, pharmaceutical companies, and research institutions globally, emphasizing markets in North America, Europe, and Asia. PROMEDIGEN's revenue model is built on partnerships with pharmaceutical companies and research organizations, focusing on B2B transactions.
The company provides access to its patented protein engineering platform and develops tailored solutions through licensing agreements and joint development arrangements. Revenue streams include upfront payments, milestone payments, and royalties. As PROMEDIGEN's products advance through clinical stages, potential revenue is anticipated from its primary candidates addressing oncogenic transcription factor modulation and drug resistance. Following its recent funding of KRW 2 billion in June 2020, PROMEDIGEN plans to enhance its product offerings, focusing on new therapies for cancer and neurodegenerative diseases.
The company aims to expand its presence in North America, Europe, and Asia by 2022, capitalizing on the growing demand for advanced cancer treatments. The funding will support the further development of its proprietary technologies and the exploration of new markets.
Current Investors
Company K Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Biotechnology
Website
www.promedigen.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.